Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240239 | 1.00 | OPRL1 (0.75) | OPRL1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL2242811 | 0.87 | OPRL1 (0.77) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL2242815 | 0.87 | OPRL1 (0.77) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL2238940 | 0.87 | OPRL1 (0.79) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL2238943 | 0.87 | OPRL1 (0.79) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL2242979 | 0.86 | OPRL1 (0.85) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL2242983 | 0.86 | OPRL1 (0.85) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL27785830 | 0.86 | OPRL1 (0.72) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL1711153 | 0.85 | OPRL1 (1.00) | OPRL1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL29408438 | 0.85 | OPRL1 (1.00) | OPRL1OPRM1OPRD1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069382-A1 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | US | claimed |
| US-8003669-B2 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069382-A1 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | ADH1A, ADH1C, ADH5 | OPRL1 292/4885OPRM1 13/4885OPRD1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.